Who is sponsoring NCT06349356?

NCT06349356 is sponsored by Quantel Medical.

What drugs are being tested in NCT06349356?

Interventions in NCT06349356: Intense pulsed light with C.STIM device.

What condition does NCT06349356 study?

NCT06349356 studies Dry Eye Disease.

Is NCT06349356 still recruiting?

NCT06349356 is currently completed. Last updated 10 December 2024.

Last reviewed 2024-12-10 · How we verify

NCT06349356

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Evaluation of Efficacy and Safety of an Intense Pulsed Light Device to Treat Dry Eye Disease"

Completed NA Last updated 10 December 2024

What this trial tests

NA trial testing Intense pulsed light with C.STIM device in Dry Eye Disease in 101 participants. Completed in 11 July 2024.

Timeline

28 March 2023

Primary endpoint
11 July 2024

11 July 2024

Quick facts

Lead sponsor	Quantel Medical
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	101
Start date	28 March 2023
Primary completion	11 July 2024
Estimated completion	11 July 2024
Sites	4 locations across United States

Drugs / interventions tested

Intense pulsed light with C.STIM device

Conditions studied

Dry Eye Disease — all drugs for Dry Eye Disease →

Sponsor

Quantel Medical

Who can join

22 and older, any sex, with Dry Eye Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the efficacy and safety of C.STIM, an intense pulsed light device to treat signs and symptoms of dry eye disease. The main question it aims to answer is: • Difference of the evolution of Tear Break-Up time (TBUT) between the 2 arms of the study (placebo and treated). Researchers will compare treated group and placebo to respond to the main question. Participants will assess to an inclusion visit (disease evaluation purpose) and then four IPL treatment visit to finish with the last visit (disease evaluation purpose).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dry Eye Disease

Currently open trials in the same condition.

NCT06596733 — Vit-A-Vision® Clinical Investigation · NA · recruiting
NCT07264517 — Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). · Phase 2 · recruiting
NCT07025811 — A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment · Phase 4 · recruiting
NCT04946721 — 2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD · recruiting
NCT06696625 — Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06349356 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Quantel Medical
Last refreshed: 10 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06349356.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing